Here's what we'll cover
Here's what we'll cover
Why Wall Street Is Talking About Wegovy Dropouts
You might not track stock analyst reports as part of your weight loss journey. But when Bank of America warns that patient dropout from Wegovy could put a major dent in Hims & Hers' second-half earnings, it tells you something important about the GLP-1 medication landscape.
The term analysts are using is "churn." In business terms, churn simply means customers stopping a subscription. In this case, the subscription is a GLP-1 medication like semaglutide (the active ingredient in Wegovy and Ozempic), and the customers are real patients who started treatment and then stopped.
This is not just a Wall Street story. It is a patient story. And understanding what drives GLP-1 churn can help you make smarter decisions about your own treatment.
What Is GLP-1 Churn, and Why Does It Happen?
GLP-1 churn refers to patients discontinuing their GLP-1 medication before reaching or sustaining their health goals. Studies have shown that a significant portion of people who start GLP-1 receptor agonists stop within the first year, often within the first few months.
There are several common reasons this happens:
Cost Without Coverage
Wegovy can cost over $1,300 per month without insurance. Even on telehealth platforms offering compounded semaglutide at lower prices, the ongoing monthly cost is a barrier. When the compounded semaglutide shortage ended and the FDA restricted its availability, many patients using lower-cost compounded versions faced a difficult choice: pay full brand-name prices or stop treatment.
Side Effects in the Early Weeks
Nausea, fatigue, and gastrointestinal discomfort are common, especially during dose escalation. Without proactive guidance from a clinician, patients often interpret these as signs to stop rather than normal parts of the adjustment period.
Lack of Ongoing Support
Many telehealth platforms offer a quick prescribing visit and a medication refill model, but limited behavioral or nutritional support. When progress slows or side effects appear, patients without access to regular check-ins are more likely to quit.
What the Hims & Hers Situation Actually Reveals
Hims & Hers built a significant portion of its recent growth around GLP-1 medication subscriptions, including compounded semaglutide. When the FDA moved to end compounded semaglutide availability in 2025, Hims & Hers had to transition users toward branded options like Wegovy or adjust its business model quickly.
Bank of America's concern is straightforward: if patients are churning off Wegovy, the revenue Hims & Hers was counting on in the second half of the year may not materialize. That is a financial problem for investors. But for patients, it surfaces a different set of questions.
What Happens to Your Access If a Platform Struggles?
Telehealth companies are businesses. When revenue projections fall short, platforms may cut programs, raise prices, reduce clinical staff, or exit certain medication categories altogether. Patients who have built their GLP-1 routine around a single platform can be left scrambling for a new provider, new prescriptions, and sometimes a coverage gap.
This is not a hypothetical. It has already happened to patients who relied on telehealth platforms that abruptly discontinued their compounded GLP-1 programs after the FDA's enforcement actions in 2025.
The Compounded Semaglutide Transition Problem
Many patients who started on compounded semaglutide through platforms like Hims & Hers were paying significantly less than the cost of branded Wegovy. When those options became restricted, some patients were offered branded Wegovy at prices they could not sustain. Others were offered novel formulations that did not have the same clinical track record. The transition was rough for many.
If you are currently using a telehealth platform for GLP-1 medications, it is worth knowing what your provider's plan is if its business model shifts or if medication access changes.
How to Evaluate a GLP-1 Telehealth Provider Beyond Price
Price matters. But it is not the only thing that matters when choosing a provider for long-term medication management. Here is a framework to help you assess any telehealth platform before committing.
The Real Cost of Stopping GLP-1 Medication Early
Research consistently shows that stopping GLP-1 medication often leads to weight regain. A study published in the journal Diabetes, Obesity and Metabolism found that participants who stopped semaglutide regained the majority of their lost weight within a year.
This is not a character flaw. It reflects the biology of how GLP-1 medications work. They help regulate appetite and blood sugar in ways that require ongoing treatment for many people, similar to how blood pressure medication requires continued use to maintain its effect.
Churn is expensive in every sense. You lose progress, you pay for restart costs, and the emotional toll of cycling on and off medication is real. Choosing a provider that actively works to keep you on track, not just one that ships you a monthly refill, makes a measurable difference in outcomes.
What the Wegovy Churn Warning Means for Medication Costs
The financial pressure on platforms like Hims & Hers may push telehealth companies to renegotiate pricing, change their medication offerings, or introduce new products to retain subscribers. For patients, this could go either way.
On one hand, competition between telehealth platforms has historically driven down the cost of GLP-1 access for patients without insurance coverage. On the other hand, if platforms lose revenue from Wegovy users churning off, some may shift toward offerings with higher margins that are not necessarily better clinical fits.
What You Can Do Right Now
- Check whether your current or prospective platform offers multiple GLP-1 options, not just one branded product, so you have flexibility if availability changes
- Ask about GLP-1 coupons and manufacturer savings programs, which can dramatically reduce Wegovy's out-of-pocket cost before you assume a price is fixed
- Compare providers on clinical support quality, not just monthly subscription price, since access to a clinician between visits is one of the most important factors in staying on track
- Ask your clinician directly what the plan is if your current medication option changes or becomes unavailable, so you are not caught without a transition plan
Branded vs. Compounded GLP-1s: Where Things Stand
The FDA's 2025 enforcement actions removed most compounded semaglutide from the market, ending a period when patients could access lower-cost alternatives through telehealth platforms. Compounded tirzepatide (the active ingredient in Mounjaro and Zepbound) is also under regulatory scrutiny.
Here is a simplified comparison of the current branded GLP-1 options relevant to weight loss:
Prices vary based on dose, pharmacy, and whether you use a savings card or insurance. Always check the manufacturer's website and compare GLP-1 coupons before paying list price.
Questions to Ask Your Provider Before Starting or Switching
Whether you are evaluating Hims & Hers or any other telehealth platform, these questions can help you make a more informed choice:
- What GLP-1 medications do you currently prescribe, and what is your plan if availability changes?
- How do you handle side effects during the first few weeks of treatment?
- Is there a clinician I can contact between scheduled visits?
- Do you offer any support beyond medication, such as nutrition guidance or behavioral coaching?
- How do you help patients who cannot afford the full list price of branded medications?
- What happens to my prescription if I need to pause treatment for financial reasons?
These are not trick questions. A quality provider will have clear, patient-centered answers to all of them.
No waiting list. No insurance needed.
Frequently Asked Questions
Why are so many people stopping Wegovy after starting it?
The most common reasons people stop Wegovy include the high out-of-pocket cost without insurance, gastrointestinal side effects during the early weeks, and a lack of ongoing clinical support to help manage the adjustment period. Without proactive guidance, many patients interpret normal early side effects as reasons to stop.
Does stopping Wegovy cause weight regain?
Yes, research shows that most people regain a significant portion of lost weight after stopping semaglutide. This is because GLP-1 medications work by actively regulating appetite and metabolism, effects that diminish when the medication is discontinued. This is why long-term treatment planning matters.
Is Hims & Hers still offering GLP-1 medications after the compounded semaglutide ban?
Hims & Hers transitioned away from standard compounded semaglutide following FDA enforcement actions in 2025. The platform has continued offering GLP-1 related services, but the exact medication options and pricing have evolved. It is worth checking their current offerings directly and comparing them with other providers.
What is the cheapest way to get Wegovy right now?
Novo Nordisk's savings program can reduce Wegovy costs significantly for eligible commercially insured patients. Without insurance, Zepbound through Eli Lilly's direct-to-patient program has offered more affordable access. GLP-1 coupon programs and pharmacy discount cards can also reduce costs at certain pharmacies.
How do I know if a telehealth GLP-1 provider is trustworthy?
Look for providers that employ licensed clinicians, offer ongoing support between visits, have transparent pricing, and clearly explain what happens if your medication becomes unavailable. Avoid platforms that offer a prescription with minimal evaluation or no follow-up care structure.
Is Ozempic the same as Wegovy for weight loss?
Both contain semaglutide, but they are not identical. Wegovy is FDA-approved for chronic weight management and comes in higher doses (up to 2.4 mg weekly). Ozempic is approved for type 2 diabetes and is sometimes prescribed off-label for weight loss. Your clinician can help determine which is appropriate for your situation.
The Bottom Line: What This Means for Your GLP-1 Journey
The story of Hims & Hers and Wegovy churn is really a story about what happens when business models collide with the real biology of weight loss treatment. GLP-1 medications like semaglutide and tirzepatide require long-term use for most people to sustain meaningful results. Platforms that built subscriber growth around low-cost compounded versions are now navigating a more complicated landscape.
For you as a patient, the takeaway is not to panic. It is to plan.
The best way to protect your GLP-1 treatment is to choose a provider based on clinical quality and medication flexibility, not just the lowest monthly price. Understand what your options are if the platform you use changes its offerings. Know how to access savings programs and compare pharmacies. And stay in close communication with your clinician, especially during transitions.
The financial pressure on telehealth companies may ease, or it may intensify. Either way, your job is to make sure your access to effective, ongoing treatment does not depend entirely on one platform's revenue projections.
If you are currently comparing GLP-1 providers, browse our provider comparison tool to see how platforms differ on medication options, clinical support, and pricing. If cost is your biggest barrier, check the latest GLP-1 coupons and savings programs before paying list price. And if you are still deciding between medications, our guides on Wegovy, Ozempic, and Mounjaro can help you have a more informed conversation with your doctor.
Always consult your physician before starting, stopping, or switching any GLP-1 medication. Your health decisions should be guided by your clinical picture, not by a company's quarterly earnings report.